Bloomberg Government reported today that the U.S. Department of Health and Human Services will implement a revised 340B rebate pilot beginning Jan. 1, 2027. The model will require health centers and other covered entities to pay full price for certain drugs and later seek rebates, raising serious concerns about cash-flow disruptions, administrative burdens and the potential diversion of resources from patient care.
While pharmaceutical manufacturers support the mode, health care organizations. including ACH, are urging Congress to intervene before it takes effect.
ACH’s statement from CEO Amanda Pears Kelly was highlighted: “Congress must act immediately before implementation to delay the rebate model and protect health centers and the patients they serve,” she said. “Any 340B reform should preserve timely access to savings and ensure health centers can continue investing those resources in the communities that rely on them.”